Letter | Published:

A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication

Nature Medicine volume 21, pages 383388 (2015) | Download Citation

Subjects

Abstract

Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (2%) engaged in the cell cycle in the first year of life1,2,3,4. In embryonic life and after early childhood, beta cell replication is barely detectable. Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts1,2,3,4,5,6,7,8. Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo. Here, using a high-throughput small-molecule screen (HTS), we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation. Using three different mouse and human islet in vivo–based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy. Enhancing the potency and beta cell specificity of these compounds are important future challenges.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & Beta cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49, 1325–1333 (2000).

  2. 2.

    et al. Beta cell replication is the primary mechanism subserving the postnatal expansion of beta cell mass in humans. Diabetes 57, 1584–1594 (2008).

  3. 3.

    et al. Cell cycle control of beta cell replication in the prenatal and postnatal human pancreas. Am. J. Physiol. Endocrinol. Metab. 300, E221–E230 (2011).

  4. 4.

    et al. Formation of a human beta cell population within pancreatic islets is set early in life. J. Clin. Endocrinol. Metab. 97, 3197–3206 (2012).

  5. 5.

    et al. Beta cell deficit and increased beta cell apoptosis in humans with diabetes. Diabetes 52, 102–110 (2003).

  6. 6.

    et al. Beta cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 36, 111–117 (2013).

  7. 7.

    , , & Human β-cell proliferation and intracellular signaling: driving in the dark without a roadmap. Diabetes 61, 2205–2213 (2012).

  8. 8.

    , , & Human β-Cell proliferation and intracellular signaling part 2: still driving in the dark without a roadmap. Diabetes 63, 819–831 (2014).

  9. 9.

    & The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 20, 91–95 (2010).

  10. 10.

    & The c-myc promoter: still MysterY and Challenge. Adv. Cancer Res. 99, 113–333 (2008).

  11. 11.

    , & Myc and cell cycle control. Biochim. Biophys. Acta (2014).

  12. 12.

    , & Suppression of myc-induced apoptosis in beta cells exposes multiple oncogenic properties of myc and triggers carcinogenic progression. Cell 109, 321–334 (2002).

  13. 13.

    & Oncogenic co-operation in β-cell tumorigenesis. Endocr. Relat. Cancer 8, 307–314 (2001).

  14. 14.

    et al. Bcl-XL gain of function and p19ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell 10, 113–120 (2006).

  15. 15.

    et al. Overexpression of c-myc in beta cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression and diabetes. Diabetes 51, 1793–1804 (2002).

  16. 16.

    et al. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes 57, 958–966 (2008).

  17. 17.

    et al. cMyc is the principal upstream driver of beta cell proliferation in rat insulinoma cell lines and Is an effective mediator of human beta cell replication. Mol. Endocrinol. 25, 1760–1772 (2011).

  18. 18.

    et al. Median absolute deviation to improve hit selection for genome-scale RNAi screens. J. Biomol. Screen. 13, 149–158 (2008).

  19. 19.

    , & Data analysis approaches in high throughput screening. in Drug Discovery Ch. 7, (2013).

  20. 20.

    & Activation, regulation and inhibition of Dyrk1a. FEBS J. 278, 246–256 (2011).

  21. 21.

    et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1a. Nat. Commun. 1, 86 (2010).

  22. 22.

    et al. Selectivity, co-crystal structures and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312–9330 (2012).

  23. 23.

    et al. Mechanism of dual specificity kinase activity of Dyrk1a. FEBS J. 280, 4495–4511 (2013).

  24. 24.

    et al. Human cdc2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr. Drug Targets 15, 539–550 (2014).

  25. 25.

    et al. Small molecule inducer of beta cell proliferation identified by high-throughput screening. J. Am. Chem. Soc. 135, 1669–1672 (2013).

  26. 26.

    , & Lymphocyte calcium signaling from membrane to nucleus. Nat. Immunol. 7, 25–32 (2006).

  27. 27.

    et al. Calcineurin/NFAT signaling regulates pancreatic β-cell growth and function. Nature 443, 345–349 (2006).

  28. 28.

    et al. Neonatal beta cell development in mice and humans is regulated by calcineurin/NFaT. Dev. Cell 23, 21–34 (2012).

  29. 29.

    , , , & Specific glucose-induced control of insulin receptor-supstrate-2 expression is mediated by Ca2+-dependent calcineurin-NFAT signaling in primary pancreatic islet β-cells. Diabetes 60, 2892–2902 (2011).

  30. 30.

    et al. Cell-type, allelic and genetic signatures in the human pancreatic beta cell transcriptome. Genome Res. 23, 1554–1562 (2013).

  31. 31.

    et al. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 6, 2399–2408 (2007).

  32. 32.

    et al. Analysis of cMYC function in normal cells via conditional gene-targeted mutation. Immunity 14, 45–55 (2001).

  33. 33.

    et al. Dyrk1a haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 22, 6636–6647 (2002).

  34. 34.

    et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia 57, 960–969 (2014).

  35. 35.

    et al. Dyrk1a induces pancreatic beta cell mass expansion and improves glucose tolerance. Cell Cycle 13, 2221–2229 (2014).

  36. 36.

    & Developments in harmine pharmacology – implications for ayahuasca use and drug-dependence treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 263–272 (2012).

  37. 37.

    et al. The small molecule harmine is an antidiabetic cell-type specific regulator of PPARγ expression. Cell Metab. 5, 357–370 (2007).

  38. 38.

    et al. GABA promotes human beta-cell proliferation and modulates glucose homeostasis. Diabetes 63, 4197–4205 (2014).

  39. 39.

    et al. Identification of small molecule inducers of pancreatic beta cell proliferation. Proc. Natl. Acad. Sci. USA 106, 1427–1432 (2009).

  40. 40.

    et al. Menin determines K-Ras proliferative outputs in endocrine cells. J. Clin. Invest. 124, 4093–4101 (2014).

  41. 41.

    et al. Identification of cMyc as a target of the APC pathway. Science 281, 1509–1512 (1998).

  42. 42.

    , & A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).

  43. 43.

    , , & Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).

  44. 44.

    & Methods in pancreatic islet separation. in Methods in Cell Transplantation (ed. Ricordi, C.) 433–438 (R.G. Landes Co, Austin, Texas), (2000).

  45. 45.

    et al. Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines. Diabetes 57, 3056–3068 (2008).

  46. 46.

    et al. ChREBP mediates glucose-stimulated pancreatic beta cell proliferation. Diabetes 61, 2004–2015 (2012).

  47. 47.

    et al. Hepatocyte growth factor (HGF) enhances engraftment and function of non-human primate islets. Diabetes 57, 2745–2754 (2008).

  48. 48.

    et al. A survey of the human pancreatic beta cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta cell replication and function in vivo. Diabetes 58, 882–893 (2009).

  49. 49.

    et al. Induction of human beta cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 59, 1926–1936 (2010).

  50. 50.

    et al. Regulation of pancreatic beta cell regeneration in the normoglycemic 60% pancreatectomy mouse. Diabetes 55, 3289–3298 (2006).

  51. 51.

    et al. Hepatocyte growth factor/c-Met signaling is required for β-cell regeneration. Diabetes 63, 216–223 (2014).

Download references

Acknowledgements

The authors wish to thank R. Vasavada, N. Fiaschi-Taesch, H. Chen, K. Takane, M. Ohlmeyer, R. DeVita, E. Schadt, C. Argmann, B. Losic, D. Lebeche, S. Kim and B. Wagner for their many helpful discussions during this study. We thank the NIDDK-supported Integrated Islet Distribution Program (IIDP), T. Kin at the University of Alberta in Edmonton and P. Witkowski at the University of Chicago for providing human islets. Ad.GFP and Ad.NFATC1 were provided by D. Lebeche (Icahn School of Medicine at Mount Sinai). This work was supported by grants from the National Institutes of Health (R-01 DK55023 (A.F.S.), U-01 DK089538 (A.F.S.), R-01 DK065149 (D.K.S.), R-01 DK067351 (A.G.-O.) and R-01 DK077096 (A.G.-O.)), the JDRF (17-2011-598 and 1-2011-603 (A.F.S.)) and the American Diabetes Association (1-14-BS-059) (A.G.-O.).

Author information

Affiliations

  1. Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • Peng Wang
    • , Juan-Carlos Alvarez-Perez
    • , Hongtao Liu
    • , Aaron Bender
    • , Anil Kumar
    • , Donald K Scott
    • , Adolfo Garcia-Ocaña
    •  & Andrew F Stewart
  2. Division of Endocrinology and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • Peng Wang
    • , Juan-Carlos Alvarez-Perez
    • , Aaron Bender
    • , Anil Kumar
    • , Donald K Scott
    • , Adolfo Garcia-Ocaña
    •  & Andrew F Stewart
  3. Experimental Therapeutics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • Dan P Felsenfeld
    • , Sharmila Sivendran
    •  & Roberto Sanchez
  4. Integrated Screening Core, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • Dan P Felsenfeld
    •  & Sharmila Sivendran
  5. Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • Donald K Scott
    •  & Adolfo Garcia-Ocaña

Authors

  1. Search for Peng Wang in:

  2. Search for Juan-Carlos Alvarez-Perez in:

  3. Search for Dan P Felsenfeld in:

  4. Search for Hongtao Liu in:

  5. Search for Sharmila Sivendran in:

  6. Search for Aaron Bender in:

  7. Search for Anil Kumar in:

  8. Search for Roberto Sanchez in:

  9. Search for Donald K Scott in:

  10. Search for Adolfo Garcia-Ocaña in:

  11. Search for Andrew F Stewart in:

Contributions

P.W., J.-C.A.-P., D.P.F., H.L., S.S., A.B., A.K., R.S., D.K.S., A.G.-O. and A.F.S. designed and performed experiments. P.W., A.G.-O. and A.F.S. wrote the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Andrew F Stewart.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9 and Supplementary Table 1

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.3820

Further reading